Shanghai Henlius Biotech

Stories

Henlius reports positive U.S. bridging trial results for lung cancer drug serplulimab

Developer of serplulimab, seeking U.S. regulatory path

A randomized U.S. trial in extensive-stage small cell lung cancer (ES-SCLC) found patients on Henlius' serplulimab lived a median 12.4 months, versus 10.2 months for Genentech's atezolizumab. The 201-patient study was a bridging trial meant to test whether global evidence for serplulimab holds in American patients.

Updated Oct 29